Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer

The approval of upfront abiraterone for castration-sensitive prostate cancer and the approval of enzalutamide and apalutamide for non-metastatic castration-resistant prostate cancer have led to early utilization of potent androgen receptor (AR) signaling inhibitors in treating advanced prostate canc...

Full description

Bibliographic Details
Main Authors: Jacob J. Adashek, Rohit K. Jain, Jingsong Zhang
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Cells
Subjects:
PARP inhibitors
DNA damage repair deficiency
prostate cancer
targeted therapy
Online Access:https://www.mdpi.com/2073-4409/8/8/860

Internet

https://www.mdpi.com/2073-4409/8/8/860

Similar Items